How to Verify MIT Tablets and Extracts During the 7-OH Scheduling Process
Record the item's physical format, label fields, source or finished-product documentation, and current rules without relying on marketing language. The same record-matching process applies to MIT chewable tablets and extract powders.
Product verification is separate from product use. The checklist below covers purchasing and document matching only; it does not provide serving instructions, effect comparisons, conversions, tapering information, or medical advice.
MIT and 7-OH are different active compounds
MIT products concentrate mitragynine, a psychoactive kratom alkaloid. Concentrated 7-OH products deliver a different compound with greater mu-opioid-receptor potency. A buyer should therefore verify the named compound, unit basis, source-versus-finished-product documentation, and 7-OH result instead of treating the two product types as interchangeable.
Verification establishes identity and document scope; it does not make concentrated MIT inactive or risk-free.
1. Record the complete product identity
- Full product title.
- Standard or bulk quantity lane.
- Physical format: chewable tablet or extract powder.
- Labeled MIT option or extract product line.
- Flavor or unflavored option.
- Tablet count or powder net weight.
- SKU when shown.
Do not reduce the record to a single number. A 150mg MIT product-line label, 90% powder product-line name, 25-tablet count, and 1g net weight identify different fields. Keeping them separate prevents a label field from being mistaken for an analytical result.
2. Identify what the document tested
| Document relationship | Useful statement | Limit |
|---|---|---|
| Finished-product report | The identified finished item or lot was submitted for the listed analyses | Still limited to the identified sample and report scope |
| Source-material report | The identified input material was submitted for the listed analyses | Does not independently test the finished tablet or package |
| Shared product-line reference | Related listings currently point to one source document | Does not establish independent testing of every option or lot |
| No matching report | No product-specific analytical statement should be made | Marketing language cannot replace missing evidence |
3. Match the identifiers
- Open the current product listing rather than an old screenshot.
- Write down the report or sample reference displayed by the store.
- Open the complete document and match the submitted sample name and sample ID.
- Confirm the report date and tested matrix.
- Confirm that any product-stage statement says source material or finished product accurately.
- Save the order date with the document reference because relationships can change.
4. Read 7-OH results with the method limits
A result such as ND must stay connected to the LOD, LOQ, units, and sample. The current MIT 90% extract-powder report identifies sample DD00126B(15) / SD260715-011 (142956) and lists 7-hydroxymitragynine as ND with a 0.008 ppm LOD and 0.025 ppm LOQ. Open the current powder COA. That statement is more informative and more accurate than saying simply contains no 7-OH.
For a full explanation, read What ND Means on a 7-OH Lab Report.
5. Keep the tablet relationship precise
The current finished-tablet report identifies pressed Mitragynine Tablet lot M/150/002 and lists 146 mg mitragynine, 0.148 mg 7-hydroxymitragynine, and 153 mg total Mitragyna alkaloids per unit. Open the finished-tablet COA. The report does not identify Mango flavor and is not presented as a legal certification or equivalency claim.
- Acceptable: the finished-tablet report for lot M/150/002 lists 146 mg mitragynine per unit.
- Acceptable: the source concentrate report lists 7-OH as ND under its stated method and limits.
- Not established: the laboratory tested every finished tablet or flavor.
- Not established: the selector value is an independently verified per-tablet assay.
- Not established: the source report determines federal, state, or local legality.
6. Check the current regulatory document
The federal record now has two procedural lanes. DEA's August 26, 2026 temporary order placed mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I; it did not place mitragynine itself in Schedule I. The separate proposed threshold for 7-OH remains pending, with HHS comments extended through September 10, 2026. Use the DEA 7-OH Scheduling Tracker for the controlling documents. Do not rely on a product page or social post as the legal source.
Destination rules can differ from federal scheduling. State, county, city, shipping, payment, and retail rules may use different product definitions. A visible product page does not guarantee that an item can be shipped to every location.
7. Watch for overbroad badges and claims
- FDA approved.
- DEA compliant.
- Guaranteed legal everywhere.
- Schedule-proof.
- Zero 7-OH without a qualified sample statement.
- Same effect or equivalent strength.
- Lab certified when the document reports a sample result rather than a certification.
8. Preserve the record after ordering
Keep the original product label, order confirmation, selected variant, report reference, and any printed lot information together. For larger tablet orders, the existing receiving checklist provides fields for package condition, count, option, flavor, and discrepancies.
When the document relationship changes
A different concentrate lot requires a new source reference. Finished-tablet testing would be a separate evidence layer and would not change what the older source report tested. If no current record matches an item, no report from a nearby product should be treated as a substitute.
A final verification pass
Before relying on a page, ask whether the selected item, linked record, submitted material, and date form one traceable chain. Then check whether every conclusion stays within that chain. A source result can support a qualified source statement; a finished-product result can support a qualified finished-product statement; neither alone supplies a medical conclusion, an effect comparison, or a guarantee about future lots.
Keep the original package identity attached to any saved record. A screenshot without the selected variant, a cropped report without its sample ID, or a note without the review date can break the chain later. Complete records are especially important when several flavors, counts, product lines, or source lots share similar names.
Continue with the Bulk MIT Tablet Receiving Checklist, MIT Products Guide, or MIT Product Documents & COA Center.
Official sources and further reading
- DEA July 1, 2026 announcement
- Federal Register notice for 7-OH above specified thresholds
- Federal Register notice for mitragynine pseudoindoxyl, MGM-15, and MGM-16
- FDA consumer information about enhanced 7-OH products
- FDA and Kratom
This checklist supports product and document matching. It does not provide medical, serving, equivalency, or legal advice.
